ExOne Co (XONE), SodaStream International Ltd (SODA), Dendreon Corporation (DNDN): Three Stocks That Could Make Huge Moves This Earnings Season

Provenge, the company’s only FDA approved drug — which treats prostate cancer — has had terribly disappointing sales. Part of that may have to do with the $93,000-per-year price tag attached to the drug (yes, you read that number right).

There could be good news in store for the company, as European regulators are have endorsed the use of Provenge in the continent. But there’s no way to tell if the drug will experience a fate in Europe similar to that which it has experienced stateside. Either, don’t expect to see Europe move the needle until later earnings statements.

Fool contributor Brian Stoffel owns shares of 3D Systems and Stratasys. The Motley Fool recommends 3D Systems, SodaStream, Stratasys, and ExOne; owns shares of 3D Systems, Dendreon, SodaStream, and Stratasys; and has options on 3D Systems.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.